HC Wainwright Reaffirms “Buy” Rating for Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $2.00 target price on the biotechnology company’s stock.

Separately, StockNews.com started coverage on Aptose Biosciences in a report on Sunday, February 9th. They set a “hold” rating on the stock.

Aptose Biosciences Stock Down 8.8 %

Shares of APTO stock opened at $0.21 on Wednesday. The firm has a market capitalization of $12.56 million, a P/E ratio of -0.07 and a beta of 0.88. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.08. The stock’s fifty day simple moving average is $0.21 and its 200 day simple moving average is $0.32.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.